DUBLIN, April 18, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Antibody Conjugates Drugs Market 2016-2020" report to their offering.
The global ADCs market is expected to grow at a CAGR of 41.58% during the period 2016-2020.
Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.
Strategic alliances, in terms of collaboration and licensing, help co-develop and commercialize drugs in different regions. Co-development agreements between companies enable the use of technical expertise from both companies. It also allows the use of regulatory and development experience gained by one company for the support of the pipeline candidates of the other company. Such agreements ensure the in-flow of adequate funds for both the companies and help reduce the liability costs of individual companies in case of failures, attracting more venture investments.
According to the report, products in the late pipeline stages will likely be launched during the forecast period. Some of these products include glembatumumab vedotin by Seattle Genetics, trastuzumab by Synthon Biopharmaceuticals, and SGN-35 by Takeda Pharmaceuticals. Some molecules are in the Phase I/II, preclinical, and discovery stages. ADCETRIS is currently under clinical trials for additional indications such as frontline mature T-cell lymphomas, B-cell lymphomas, and CD30-expressing conditions.
Further, the report states that the high developmental costs of antibody conjugates negatively impact the growth of the market.
Key questions answered in this report:
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
- F. Hoffmann-La Roche AG
- Seattle Genetics Inc.
- Takeda Pharmaceutical Company
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Overview of ADCs
PART 06: Pipeline portfolios
PART 07: Market landscape
PART 08: Market segmentation by MOA
PART 09: Market segmentation by technologies used in ADCs
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
For more information visit
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-antibody-conjugates-drugs-market-2016-2020---high-developmental-costs----research-and-markets-300252784.html
SOURCE Research and Markets